Hosted on MSN3m
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4%
Amylin therapies are considered the next generation of obesity medication from the current GLP-1 products sold by Danish drug ...
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo stock slides 4%
The news sent Roche's stock up more than 4% in trading Wednesday, and Zealand's stock skyrocketed 40% on the news. Meanwhile, Novo Nordisk's stock was hit, sliding 4%, and Eli Lilly's stock was down ...